Diagnostic Performance of 68Ga-PSMA-11 Positron-emission-tomography/Computed-tomography in a Large Cohort of Patients with Biochemical Recurrence of Prostate Carcinoma. Issue 1 (July 2020)

• Record Type: Journal Article
• Authors: Hoffmann, Manuela A.; Buchholz, Hans-Georg; Wieler, Helmut J.; Müller-Hübenthal, Jonas; Trampert, Ludwin; Richardsen, Ines; Schreckenberger, Mathias
• Is Part Of: Health physics. Volume 119:Issue 1(2020)
• Publication Date: 2020-07
• Subjects: cancer -- computed tomography -- diagnostic imaging -- positron emission tomography; Biophysics -- Periodicals; Health Physics -- periodicals; Radiation Protection -- periodicals; Radiotherapy -- periodicals; Medische fysica; Electronic journals; 612.01448
• DOI: 10.1097/HP.0000000000001253
• Languages: English
• ISSNs: 0017-9078

Abstract

Abstract : Abstract: Gallium-68 ( 68 Ga) prostate-specific-membrane-antigen positron-emission-tomography/computed-tomography is a highly promising method for imaging primary and recurrent prostate cancer. These dual-modality imaging technologies enable whole-body functional and anatomical evaluation in a single session. This study investigated the performance of 68 Ga-prostate-specific-membrane-antigen-11 positron-emission-tomography/computed-tomography for detecting prostate carcinoma in patients with rising prostate-specific-antigen after primary therapy. Six hundred sixty (660) patients with biochemical recurrence referred for positron-emission-tomography/computed-tomography with 68 Ga-prostate-specific-membrane-antigen-11 were evaluated retrospectively. Prostate-specific-antigen-stratified cohorts of pathological scan results were analyzed, and relationships between prostate-specific-antigen kinetics and PSMA-positive tumor lesions were correlated. Gallium-68 prostate-specific-membrane-antigen-11 positron-emission-tomography/computed-tomography showed a pathological prostate-specific-membrane-antigen uptake in 76% (500 of 660 patients). Positive scans were positively associated with prostate-specific-antigen (p<0.001). For patients with prostate-specific-antigen <0.2 ng mL −1, the PSMA-positive tumor lesions rate was 41%. Patients with prostate-specific-antigen of 0.2–<0.5 ng mL −1, 0.5–<1.0 ng mL −1, 1.0–<2.0 ng mL −1, and 2.0–<5.0 ng mL −1 showed rates of 44.7%, 61.7%, 72.3%, 85.2%, respectively, and for prostate-specific-antigen of ≥5.0 ng mL −1 it increased to 94%. Prostate-specific-antigen velocity was also correlated with PSMA-positive tumor lesions (p<0.001). In contrast, no association was found for prostate-specific-antigen doubling time (p=0.74). PSMA-positive tumor lesions were significantly increased in patients with primary intermediate- (Gleason Score7) and high-risk (Gleason Score>7) vs. low-risk prostate cancer (Gleason Score<7) (p<0.001). Our data confirm the high performance of 68 Ga-prostate-specific-membrane-antigen positron-emission-tomography/computed-tomography for the detection of recurrent prostate cancer. This may alter treatment planning and has been documented in other studies as well.